-+ 0.00%
-+ 0.00%
-+ 0.00%

*Tvardi Therapeutics: Topline Data From Phase 2 Trial of TTI-101 in Hepatocellular Carcinoma Anticipated in 2H

Dow Jones·03/31/2026 20:06:00

Please log in to view news